Welcome to our dedicated page for Mink Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MiNK Therapeutics, Inc. (NASDAQ: INKT) SEC filings page provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on allogeneic invariant natural killer T (iNKT) cell therapies and precision immune technologies, MiNK uses its SEC reports to describe material agreements, financing activities, governance decisions, and key clinical and corporate milestones.
Current reports on Form 8-K are particularly relevant for tracking MiNK’s business. Recent 8-K filings have covered topics such as the appointment of new board members, entry into an at-the-market equity sales agreement, the announcement of quarterly financial results, and updates on clinical and translational data for its iNKT programs. These filings often incorporate press releases that summarize clinical progress with agenT-797 in solid tumors, GvHD, and pulmonary immune failure, as well as grant awards and collaborations with academic institutions.
Investors can also use MiNK’s SEC filings to monitor capital-raising transactions, including at-the-market offerings registered on Form S-3 and described in accompanying 8-Ks, and to review governance and shareholder matters such as annual meeting results and director elections. Over time, annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide more detailed information on risk factors, research and development activities, and the financial condition of the company.
On Stock Titan, MiNK’s filings are updated in near real time from EDGAR, and AI-powered tools can help summarize lengthy documents, highlight key sections, and surface items such as material agreements or equity programs. Users can also review insider-related disclosures when Forms 3, 4, or 5 are filed, offering additional context on management and director equity activity in relation to the company’s clinical and strategic developments.
MiNK Therapeutics director Ulf Wiinberg received a grant of stock options on 09/09/2025 allowing purchase of 3,225 shares of common stock at an exercise price of $15.36 per share. The Form 4 shows the options were acquired (transaction code A) and the reporting person beneficially owns 3,225 shares following the transaction. The option term includes an expiration date shown as 09/09/2035 on the filing, and the filing discloses the option vests in full on the one‑year anniversary of the grant if the director continues to serve on the board through that date. The reporting person is identified as a director and the Form 4 was signed by an attorney‑in‑fact.
MiNK Therapeutics director Barbara Ryan received a stock option grant on 09/09/2025. The option gives the right to buy 3,225 shares of common stock at an exercise price of $15.36 per share, is exercisable beginning 09/09/2025, and expires 09/09/2035. The option vests in full on the one-year anniversary of the grant date if the reporting person continues to serve on the board. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/11/2025.
Ulf Wiinberg, a director of MiNK Therapeutics, Inc. (INKT), reported a grant and his current holdings. On 09/02/2025 Mr. Wiinberg was granted 1,011 restricted stock units (RSUs) received in lieu of cash board and committee retainers; the RSUs vest one month from the grant date and are valued at $13.86 per share on the filing. Following the grant he beneficially owns 18,971 shares directly and 27,830 shares indirectly held in an irrevocable trust for his family.
MiNK Therapeutics director Robert Peter Kadlec was granted 975 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. The RSUs, received in lieu of cash retainers, represent a contingent right to one share of common stock per RSU and will vest one month from the grant date. Following the award, the reporting person beneficially owns 17,908 shares. The transaction is reported on Form 4 for ticker INKT and was signed by an attorney-in-fact on 09/03/2025.
MiNK Therapeutics director Barbara Ryan received 1,281 restricted stock units (RSUs) as board and committee compensation on 09/02/2025. Each RSU converts to one share of common stock; the reported RSUs were granted in lieu of cash retainers and will vest one month from the grant date. Following the grant, Ms. Ryan beneficially owns 20,805 shares of common stock. The transaction price recorded for the RSUs is $13.86 per share (used for reporting purposes).
Brian Corvese, a director of MiNK Therapeutics, Inc. (INKT), was granted 1,290 restricted stock units (RSUs) on 09/02/2025 as board and committee compensation in lieu of cash. Each RSU represents a contingent right to receive one share of common stock and the grant price shown on the form is $13.86 per share. After the grant, the reporting person beneficially owns 48,441 shares. The RSUs are scheduled to vest one month from the grant date. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
MiNK Therapeutics director Peter Behner received 1,173 restricted stock units (RSUs) on 09/02/2025, granted in lieu of cash board and committee retainers. Each RSU represents a contingent right to one share of common stock and will vest one month from the grant date.
After the grant, Mr. Behner beneficially owns 18,649 shares of MiNK common stock on a direct basis. The reported per-share value associated with the grant is $13.86. The Form 4 was submitted to disclose this change in beneficial ownership.
MiNK Therapeutics (INKT) filed a Form 144 proposing the sale of 786,750 shares of common stock, with an aggregate market value of $12,572,265, to be sold approximately on 08/29/2025 on the INKT exchange. The filing states these shares were originally issued on 07/05/2017 in an original issuance from the issuer when it was a wholly owned subsidiary of Agenus Inc.; the shares were acquired in exchange for Agenus Inc.'s initial capital contribution. The filer reports no securities sold in the past three months and provides the standard representation that no undisclosed material adverse information is known.
The company may offer and sell up to an additional $36,585,515 of common stock through its at-the-market program under this updated prospectus supplement. This follows prior sales of 478,462 shares for gross proceeds of $13,414,485 under the same sales agreement with B. Riley Securities as sales agent.
The company’s public float was about $98.8 million, based on 1,539,804 shares of common stock held by non‑affiliates as of August 12, 2025, at a reference price of $64.17 per share. Because the public float now exceeds $75 million, the company is no longer subject to the Form S‑3 General Instruction I.B.6 sales limitations for this registration.
MiNK Therapeutics, Inc. filed a Form S-8 registration statement to register additional shares for its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The company states this filing does not involve a capital-raising transaction, a public offering, or a current issuance of shares. Any shares covered may be delivered only in connection with awards or purchases under these plans in accordance with their terms. The filing incorporates by reference three prior effective S-8 registrations for the same plans and includes standard exhibits such as organizational documents, plan documents, legal opinions, auditor consent, and powers of attorney.